Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 UCAR-T in Refractory Juvenile Dermatomyositis
NCT06686524Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Anti-CD19 UCAR-T cells in juvenile dermatomyositis (JDM), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 28 days, Total Improvement Score at 6 months and 4 more. Started Nov 2024; status: recruiting.
02
Drugs
Anti-CD19 UCAR-T cells
03
Conditions
juvenile dermatomyositis (JDM)
Beyond the preview
Go deeper on NCT06686524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06686524.